IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This study looks at a new treatment, **IDP-023**, for blood cancers. NK cells, a type of white blood cell, are part of this treatment. They help fight cancer cells. The study is in two parts: **Phase 1** checks the safety of the treatment with different doses, while **Phase 2** tests its effectiveness, especially when combined with other drugs like **daratumumab** for multiple myeloma (MM) or **rituximab** for non-Hodgkin's lymphoma (NHL).
To join, patients need to have MM needing treatment after 3 failed therapies or NHL with 2 failed chemotherapies. They should be able to perform daily activities (ECOG 0 or 1) and have a life expectancy of over 12 weeks. Patients with heart problems, specific infections like HIV, active hepatitis, or COVID-19 can't join.
- The study needs visits to the hospital for treatment and observation.
- Participants may receive compensation for travel and time.
- Risks include potential side effects from the treatment.
Study details
NCT06119685
Indapta Therapeutics, INC.
11 July 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.